Compared to the control group, NAFLD patients exhibited multiple metabolic disorders and abnormal liver function, with significantly elevated levels of ALT, AST, γ-glutamyl transferase, Glucose, low-density lipoprotein, and high-sensitivity C-reactive protein, and significantly decreased high-density lipoprotein levels (all P < .05). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.